Ardelyx (ARDX) EBITDA Margin (2013 - 2026)
Ardelyx's (ARDX) quarterly EBITDA Margin came in at 34.71% in Q1 2026, up 1433.0% YoY from 2.26% in Q1 2025, and down 952.4% on a QoQ basis from 4.07% in Q4 2025.
Ardelyx (ARDX) EBITDA Margin (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 12 years of EBITDA Margin data on file, last reported at 34.71% in Q1 2026.
- Quarterly EBITDA Margin rose 1433.0% year-over-year to 34.71% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.67% (down 71.0% YoY) and the FY2025 annual result came in at 10.06%, down 168.0% from the prior year.
- EBITDA Margin retreated to 34.71% in Q1 2026, from 4.07% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 137.29% in Q3 2025 to a low of 5941.67% in Q1 2022.
- A 5-year average of 457.82% and a median of 34.71% in 2026 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin tumbled 545542 bps — and 2023, when it jumped 571241 bps.
- Tracing ARDX's EBITDA Margin over 5 years: stood at 27.49% in 2022, then plunged by 396 bps to 81.44% in 2023, then jumped by 109 bps to 7.0% in 2024, then slumped by 42 bps to 4.07% in 2025, then plunged by 952 bps to 34.71% in 2026.
- The last three EBITDA Margin figures came in at 34.71% (Q1 2026), 4.07% (Q4 2025), and 137.29% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | -10.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.28% |
| Mar 31, 2026 | -34.71% |
| Dec 31, 2025 | 4.07% |
| Sep 30, 2025 | 137.29% |
| Jun 30, 2025 | -14.74% |
| Mar 31, 2025 | -49.04% |
| Dec 31, 2024 | 7.00% |
| Sep 30, 2024 | 2.27% |
| Jun 30, 2024 | -18.61% |
| Mar 31, 2024 | -53.62% |
| Dec 31, 2023 | -81.44% |
| Sep 30, 2023 | 13.12% |
| Jun 30, 2023 | -74.44% |
| Mar 31, 2023 | -229.25% |
| Dec 31, 2022 | 27.49% |
| Sep 30, 2022 | -438.83% |
| Jun 30, 2022 | -1,037.81% |
| Mar 31, 2022 | -5,941.67% |
| Dec 31, 2021 | -3,427.89% |
| Sep 30, 2021 | -3,600.68% |